Floatz logo

bi 6727

Relapsed and Refractory Aggressive B- and T-cell Lymphomas

Yale UniversityPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed and Refractory Aggressive B- and T-cell Lymphomas cohort.

Asset / SponsorPhaseRating
Belinostat
Yale University
Phase 1CC

Same molecule, other indications

bi 6727 is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →
ovarian neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →